Skip to content

Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis

Molecular Typing of Adult Community-acquired Pneumonia in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03093220
Enrollment
500
Registered
2017-03-28
Start date
2017-03-31
Completion date
2018-12-31
Last updated
2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired Infections, Genetic Disorder, Host-Pathogen Interactions, Respiratory Infections

Brief summary

Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality. As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.

Interventions

None listed

Sponsors

CapitalBio Group Corporation
CollaboratorUNKNOWN
Chinese Academy of Sciences
CollaboratorOTHER_GOV
West China Hospital
CollaboratorOTHER
Second Hospital of Jilin University
CollaboratorOTHER
Shanghai Pulmonary Hospital, Shanghai, China
CollaboratorOTHER
Peking University People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* adult (aged \> 16 years) * diagnosed as community-acquired pneumonia

Exclusion criteria

* being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy * history of long-term nursing home stays * history of recently hospitalized (\<90 days)

Design outcomes

Primary

MeasureTime frameDescription
30 day mortality30 days after the onset of CAPall-cause death in 30 days after the onset of CAP

Secondary

MeasureTime frameDescription
complications30 days after the onset of CAPnonfatal complications including critical organic or systematic dysfunction

Countries

China

Contacts

Primary ContactYali Zheng, Dr
drylzheng@gmail.com15011451515

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026